Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.78 |
| ▸ | PPARG | P37231 | 1/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.78 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.78 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.78 |
| ▸ | FLT1 | P17948 | 2/20 | 0.67 |
| ▸ | FLT4 | P35916 | 2/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9096099 | 1.00 | RAB9A (0.78) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL9486495 | 0.88 | CA12 (0.66) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL9096431 | 0.86 | RAB9A (0.59) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL9096015 | 0.85 | RAB9A (0.68) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL5187504 | 0.85 | PPARG (0.57) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL9094918 | 0.84 | FBP1 (0.57) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL5184835 | 0.84 | IDO1 (0.61) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL9096201 | 0.84 | ALDH1A1 (0.60) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| Ly-181984 SCHEMBL4612056 | 0.84 | RECQL (0.74) | RAB9APPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL4921199 | 0.83 | MAPT (0.71) | RAB9AALDH1A1TDP1HRH3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | claimed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-7939551-B2 | for diabetes mellitus and other metabolic disorders; compounds of given formula such as sulfonamides and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists | AMGEN INC. (US) | 2011-05-10 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| WO-2008124122-A1 | COMBINATIONS OF STATINS AND ANTI-OBESITY AGENT AND GLITAZONES | SCIDOSE, LLC (US) | 2008-10-16 | — | — | WO | claimed |
| US-20080249156-A1 | Combinations of statins and anti-obesity agent and glitazones | PALEPU NAGESWARA R | 2008-10-09 | — | — | US | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060035928-A1 | Combination therapeutic compositions and methods of use | AMGEN INC. (US) | 2006-02-16 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040259918-A1 | Combination therapeutic compositions and method of use | TULARIK INC. | 2004-12-23 | — | — | US | claimed |
| US-6653332-B2 | For treatment of diabetes mellitus; for example sulfonamide derivatives of given formula and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists | TULARIK INC. | 2003-11-25 | — | — | US | claimed |
| US-20020037928-A1 | Combination therapeutic compositions and method of use | AMGEN INC. | 2002-03-28 | — | — | US | claimed |
| WO-2001082916-A2 | COMBINATION THERAPEUTIC COMPOSITIONS AND METHODS OF USE | TULARIK INC. (US) | 2001-11-08 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230414452-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11806311-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| EP-4208155-A1 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149304-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145752-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230131450-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
| EP-4135712-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | Pike Therapeutics, Inc. (CA) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| US-11541002-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220347117-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2022-11-03 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3343226-B1 | BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS | PROTEOMICS INT PTY LTD (AU) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-05-26 | — | — | US | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS INC (CA) | 2021-10-21 | — | — | US | disclosed |
| WO-2021209815-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS, INC. (CA) | 2021-10-21 | — | — | WO | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021097247-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210145731-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3811371-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | Aquestive Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200345624-A1 | Nanopore Delivery Device | HUDSON LEE EDWARD (US) | 2020-11-05 | — | — | US | disclosed |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Synchronicity Pharma, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200239884-A1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | UNIV MIAMI (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200101009-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-04-02 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-10443056-B2 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation | NOGRA PHARMA LIMITED (IE) | 2019-10-15 | — | — | US | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| US-20190241540-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2019-08-08 | — | — | US | disclosed |
| US-10369340-B2 | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | NANOMEDICAL SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-2419091-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-2839004-B1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | NOGRA PHARMA LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-20190136237-A1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | NOGRA PHARMA LIMITED (IE) | 2019-05-09 | — | — | US | disclosed |
| US-20190107546-A1 | Method for Identifying an Agent for Treating Abnormal Kidney Function | PROTEOMICS INT PTY LTD (AU) | 2019-04-11 | — | — | US | disclosed |
| EP-3452597-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| CN-109462995-A | The method and composition of bioactivator | 波涛生命科学有限公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20190054024-A1 | Solid Dosage Forms | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2019-02-21 | — | — | US | disclosed |
| US-10191067-B2 | Method for identifying an agent for treating abnormal kidney function | PROTEOMICS INTERNATIONAL PTY LTD (AU) | 2019-01-29 | — | — | US | disclosed |
| US-20180334446-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-11-22 | — | — | US | disclosed |
| US-10081809-B2 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation | UNIVERSITY OF MIAMI (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180265589-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2018-09-20 | — | — | US | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3343226-A1 | BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS | Proteomics International Pty Ltd (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3151012-B1 | BIOMARKERS ASSOCIATED WITH DIABETIC NEPHROPATHY | PROTEOMICS INT PTY LTD (AU) | 2018-03-21 | — | — | EP | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319698-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2017-11-09 | — | — | US | disclosed |
| EP-2348050-B1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170299613-A1 | Use of CD5 Antigen-Like as a Biomarker for Diabetic Nephropathy | PROTEOMICS INTERNATIONAL (IP) PTY LTD (AU) | 2017-10-19 | — | — | US | disclosed |
| CN-107252492-A | The method survived after treatment diabetes and/or promotion pancreatic islets transplantation | 诺格尔制药有限公司 | 2017-10-17 | — | — | CN | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170261520-A1 | Markers Associated With Arteriovascular Events And Methods Of Use Thereof | TRUE HEALTH IP LLC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3212167-A1 | GASTRORETENTIVE GEL FORMULATIONS | Jagotec AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-107106484-A | Gastric retention gel preparation | 雅戈泰克股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-9733259-B2 | Method of assessing a subject for abnormal kidney function | PROTEOMICS INTERNATIONAL PTY LTD (AU) | 2017-08-15 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| CN-104487574-B | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation | 诺格尔制药有限公司 | 2017-07-07 | — | — | CN | disclosed |
| US-9689880-B2 | Markers associated with arteriovascular events and methods of use thereof | TRUE HEALTH IP LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| EP-3151012-A1 | BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS | Proteomics International Pty Ltd (AU) | 2017-04-05 | — | — | EP | disclosed |
| EP-3129366-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Reset Therapeutics, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9526824-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2355864-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| WO-2016100301-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175572-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3033138-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | Nanomedical Systems Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2016066256-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-9308162-B2 | Biocompatible oligomer-polymer compositions | TOLMAR THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150355198-A1 | Use of CD5 Antigen-Like as a Biomarker for Diabetic Nephropathy | PROTEOMICS INTERNATIONAL (IP) PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-20150346218-A1 | MARKERS ASSOCIATED WITH ARTERIOVASCULAR EVENTS AND METHODS OF USE THEREOF | HEALTH DIAGNOSTIC LABORATORY, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150315286-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-11-05 | — | — | US | disclosed |
| US-20150315573-A1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | UNIVERSITY OF MIAMI (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015167760-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| WO-2015157182-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2015-10-08 | — | — | US | disclosed |
| EP-2924440-A2 | MARKERS ASSOCIATED WITH ARTERIOVASCULAR EVENTS AND METHODS OF USE THEREOF | Health Diagnostic Laboratory, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| US-9146243-B2 | Method of assessing diabetic nephropathy using CD5 antigen-like | PROTEOMICS INTERNATIONAL PTY LTD (AU) | 2015-09-29 | — | — | US | disclosed |
| US-20150246174-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912070-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | Celanese Acetate LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9096743-B2 | Process for forming films, fibers, and beads from chitinous biomass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104812777-A | Polysaccharide ester microspheres and methods and articles related thereto | CELANESE ACETATE LLC | 2015-07-29 | — | — | CN | disclosed |
| US-20150193587-A1 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | INTEGRATED HEALTH LEADERS, LLC | 2015-07-09 | — | — | US | disclosed |
| EP-2891885-A2 | Diabetes-related biomarkers and methods of use thereof | Health Diagnostic Laboratory, Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| US-9068006-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-06-30 | — | — | US | disclosed |
| US-9057736-B2 | Markers associated with arteriovascular events and methods of use thereof | Health Diagnostics Laboratory, Inc. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9034585-B2 | Diabetes-related biomarkers and methods of use thereof | HEALTH DIAGNOSTIC LABORATORY, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| CN-104546669-A | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS | 2015-04-29 | — | — | CN | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2302395-B1 | Markers associated with arteriovascular events and methods of use thereof | HEALTH DIAGNOSTIC LAB INC (US) | 2015-04-15 | — | — | EP | disclosed |
| US-9005185-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2855458-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Reset Therapeutics, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8993718-B2 | Methods and compositions for detecting and modulating O-glycosylation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2839004-A1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | Nogra Pharma Limited (IE) | 2015-02-25 | — | — | EP | disclosed |
| US-20150050371-A1 | Extract Formulations of Rhodamnia Cinerea And Uses Thereof | BIOTROPICS MALAYSIA BERHAD (MY) | 2015-02-19 | — | — | US | disclosed |
| WO-2015023557-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-2291174-B1 | FLOWABLE COMPOSITION COMPRISING BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS INC (US) | 2015-01-28 | — | — | EP | disclosed |
| CN-102271732-B | Nanochannel devices and related methods | UNIV TEXAS | 2014-12-31 | — | — | CN | disclosed |
| CN-104203220-A | Device and method for sustained release of therapeutic agent | UNIV TEXAS | 2014-12-10 | — | — | CN | disclosed |
| US-20140348936-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-27 | — | — | US | disclosed |
| EP-2541254-B1 | Diabetes-related biomarkers and methods of use thereof | HEALTH DIAGNOSTIC LAB INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140328884-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140315720-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2790677-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2790678-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140249049-A1 | USE OF CD5 ANTIGEN-LIKE AS A BIOMARKER FOR DIABETIC NEPHROPATHY | PROTEOMICS INTERNATIONAL PTY LTD (AU) | 2014-09-04 | — | — | US | disclosed |
| EP-2770984-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187444-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING O-GLYCOSYLATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140180251-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140147850-A1 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| WO-2014066463-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140113826-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2717860-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI Pharma, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2014031398-A1 | BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS | TICONA LLC (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140051771-A1 | Biomedical Devices Comprising Molded Polyethylene Components | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140052264-A1 | Porous, Stabilized Craniomaxillofacial Implants and Methods and Kits Relating Thereto | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8632510-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | NUVO RESEARCH INC. (CA) | 2013-12-19 | — | — | US | disclosed |
| WO-2013170186-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| WO-2013158868-A1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130240483-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013133685-A1 | EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF | BIOTROPICS MALAYSIA BERHAD (MY) | 2013-09-12 | — | — | WO | disclosed |
| CN-103299192-A | Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions | PROTEOMICS INTERNAT PTY LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-103271083-A | Multi-functional ionic liquid compositions | UNIV ALABAMA | 2013-09-04 | — | — | CN | disclosed |
| US-8524444-B2 | Methods and compositions for detections and modulating O-glycosylation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130224211-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-29 | — | — | US | disclosed |
| US-8513304-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-08-20 | — | — | US | disclosed |
| EP-2619592-A1 | BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS | Proteomics International Pty Ltd (AU) | 2013-07-31 | — | — | EP | disclosed |
| US-20130189711-A1 | METHODS, PRODUCTS AND TREATMENTS FOR DIABETES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130177544-A1 | BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2013-07-11 | — | — | US | disclosed |
| US-8480637-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2147315-B1 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE INC (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2013090891-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090893-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| CN-101326275-B | Multifunctional ionic liquid composition | UNIV ALABAMA | 2013-06-05 | — | — | CN | disclosed |
| US-20130131628-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063004-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| US-8409816-B2 | Diabetes-related biomarkers and methods of use thereof | TETHYS BIOSCIENCE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| US-8404451-B2 | Mass spectrometric methods and products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2541254-A2 | Diabetes-related biomarkers and methods of use thereof | Tethys Bioscience, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| WO-2012170676-A1 | CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION | STI PHARMA, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8314077-B2 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8298779-B2 | Methods, products and treatments for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120179484-A1 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120115729-A1 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120095443-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-04-19 | — | — | US | disclosed |
| US-8158152-B2 | Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets | SCIDOSE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120088251-A1 | MASS SPECTROMETRIC METHODS AND PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2012037603-A1 | BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS | PROTEOMICS INTERNATIONAL PTY LTD (AU) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012027555-A2 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2419091-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8119358-B2 | Diabetes-related biomarkers and methods of use thereof | TETHYS BIOSCIENCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8101363-B2 | Obtaining a level of a marker of systemic inflammation in individual, comparing level of marker to a predetermined value specific for diagnosis of diabetes or diabetic complications, and characterizing the individual's risk profile | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| CN-102317786-A | Diabetes correlativity biological marker and method of application thereof | TETHYS BIOSCIENCE INC | 2012-01-11 | — | — | CN | disclosed |
| US-8093009-B2 | Mass spectrometric methods and products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-10 | — | — | US | disclosed |
| US-20120003754-A1 | METHODS, PRODUCTS AND TREATMENTS FOR DIABETES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-05 | — | — | US | disclosed |
| EP-1386165-B1 | INFLAMMATORY MARKERS FOR DETECTION AND PREVENTION OF DIABETES MELLITUS | BRIGHAM & WOMENS HOSPITAL (US) | 2011-11-02 | — | — | EP | disclosed |
| CN-102225046-A | Transdermal drug delivery formulation | NUVO RES INC | 2011-10-26 | — | — | CN | disclosed |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8008024-B2 | Methods, products and treatments for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2355864-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2348050-A1 | Anti-glycated CD59 antibodies and uses thereof | The President and Fellows of Harvard College (US) | 2011-07-27 | — | — | EP | disclosed |
| CN-101296691-B | Transdermal drug delivery dosage form | NUVO RES INC | 2011-07-27 | — | — | CN | disclosed |
| EP-2345672-A1 | Anti-glycated cd59 antibodies and uses thereof | The President and Fellows of Harvard College (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7976871-B2 | Modified release composition of highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-07-12 | — | — | US | disclosed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-7939551-B2 | for diabetes mellitus and other metabolic disorders; compounds of given formula such as sulfonamides and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists | AMGEN INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20110105853-A1 | SYSTEMS AND METHODS FOR HEALTHCARE DELIVERY, OBSERVATION, AND COMMUNICATION BETWEEN A DE-CENTRALIZED HEALTHCARE SYSTEM AND A PATIENT LIVING AT HOME | TLC HOLDINGS I, L.L.C. | 2011-05-05 | — | — | US | disclosed |
| EP-2302395-A1 | Markers associated with arteriovascular events and methods of use thereof | Tethys Bioscience, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2011031925-A1 | SYSTEMS AND METHODS FOR HEALTHCARE DELIVERY, OBSERVATION, AND COMMUNICATION BETWEEN A DE-CENTRALIZED HEALTHCARE SYSTEM AND A PATIENT LIVING AT HOME | CLINICALLY HOME, LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-7905852-B2 | Skin-contacting-adhesive free dressing | JENNINGS-SPRING BARBARA | 2011-03-15 | — | — | US | disclosed |
| EP-2291174-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | Tolmar Therapeutics, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110053177-A1 | MASS SPECTROMETRIC METHODS AND PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-03-03 | — | — | US | disclosed |
| US-7888116-B2 | identifying and isolating a precursor cell; of increasing insulin synthesis from a pancreatic B-cell; contacting a pancreatic cell sample with a marker that selectively binds a Notch receptor and detecting the bound marker, the cell that binds the marker being a pancreatic precursor cell | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-02-15 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110008805-A1 | Markers Associate with Arteriovascular Events and Methods of Use Thereof | TETHYS BIOSCIENCE, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010141470-A2 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100290987-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING O-GLYCOSYLATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-11-18 | — | — | US | disclosed |
| US-7833725-B2 | Mass spectrometric methods and products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2242489-A1 | COMBINATION THERAPEUTIC COMPOSITIONS AND METHOD OF USE | Messadek, Jallal (BE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010120817-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| CN-101810592-A | Contain the pharmaceutical preparation that is dispersed in the active matter in the substrate | ALTANA PHARMA AG | 2010-08-25 | — | — | CN | disclosed |
| US-7780990-B2 | Combination therapeutic compositions and method of use | MESSADEK JALLAL | 2010-08-24 | — | — | US | disclosed |
| US-7767791-B2 | Methods, products and treatments for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-08-03 | — | — | US | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| US-7723050-B2 | Diabetes-related biomarkers and methods of use thereof | TETHYS BIOSCIENCE, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2010056986-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2147315-A2 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | Tethys Bioscience, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20100009378-A1 | Mass Spectrometric Methods and Products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-31 | — | — | US | disclosed |
| WO-2009148581-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | QLT USA, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090271124-A1 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090191574-A1 | Methods, Products and Treatments for Diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-30 | — | — | US | disclosed |
| EP-2030025-A2 | MARKERS ASSOCIATED WITH ARTERIOVASCULAR EVENTS AND METHODS OF USE THEREOF | Tethys Bioscience, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090012716-A1 | Diabetes-related biomarkers and methods of use thereof | TETHYS BIOSCIENCE, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090005722-A1 | Skin-contacting-adhesive free dressing | JENNLNGS-SPRING BARBARA | 2009-01-01 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| WO-2008156676-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING O-GLYCOSYLATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-101326275-A | Multifunctional ionic liquid composition | UNIV ALABAMA (US) | 2008-12-17 | — | — | CN | disclosed |
| US-20080299088-A1 | Uses of Notch Receptors, Notch Ligands, and Notch Modulators in Methods Related to Metabolic Diseases | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-12-04 | — | — | US | disclosed |
| WO-2008137165-A1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008131224-A2 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| CN-101296691-A | transdermal drug delivery dosage form | NUVO RES INC (CA) | 2008-10-29 | — | — | CN | disclosed |
| US-7439330-B2 | Anti-glycated CD59 antibodies and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2008124122-A1 | COMBINATIONS OF STATINS AND ANTI-OBESITY AGENT AND GLITAZONES | SCIDOSE, LLC (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249156-A1 | Combinations of statins and anti-obesity agent and glitazones | PALEPU NAGESWARA R | 2008-10-09 | — | — | US | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20080057590-A1 | Markers associated with arteriovascular events and methods of use thereof | TETHYS BIOSCIENCE, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080031964-A1 | COMBINATION THERAPEUTIC COMPOSITIONS AND METHOD OF USE | MESSADEK JALLAL | 2008-02-07 | — | — | US | disclosed |
| WO-2007146229-A2 | MARKERS ASSOCIATED WITH ARTERIOVASCULAR EVENTS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| US-20070259377-A1 | Diabetes-associated markers and methods of use thereof | TETHYS BIOSCIENCE, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007120638-A2 | METHODS AND COMPOSITIONS FOR MODULATING GLYCOSYLATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1827453-A1 | SULFONYLUREA COMPOSITIONS AND A PROCESS FOR ITS PREPARATION | Themis Laboratories Private Limited (IN) | 2007-09-05 | — | — | EP | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| EP-1789449-A1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | The President and Fellows of Harvard College (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7199151-B2 | DHA-pharmaceutical agent conjugates of taxanes | LUITPOLD PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070072830-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060257936-A1 | Methods, products and treatments for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-11-16 | — | — | US | disclosed |
| WO-2006086856-A1 | COMBINATION THERAPEUTIC COMPOSITIONS AND METHOD OF USE | MESSADEK, JALLAL (BE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006086098-A2 | MASS SPECTROMETRIC METHODS AND PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006061697-A1 | SULFONYLUREA COMPOSITIONS AND A PROCESS FOR ITS PREPARATION | THEMIS LABORATORIES PRIVATE LIMITED (IN) | 2006-06-15 | — | — | WO | disclosed |
| US-7049082-B2 | Methods, products and treatments for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060094693-A1 | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions | POINT THERAPEUTICS, INC. (US) | 2006-05-04 | — | — | US | disclosed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063719-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| WO-2006023209-A2 | USES OF NOTCH RECEPTORS, NOTCH LIGANDS, AND NOTCH MODULATORS IN METHODS RELATED TO METABOLIC DISEASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060035928-A1 | Combination therapeutic compositions and methods of use | AMGEN INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | disclosed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009533-A1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| WO-2005021038-A2 | AGENT FOR TREATING METABOLIC SYNDROME | BEISEL GUENTHER (DE) | 2005-03-10 | — | — | WO | disclosed |
| US-20050032128-A1 | Anti-glycated CD59 antibodies and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-6835545-B2 | Methods, products and treatments for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-12-28 | — | — | US | disclosed |
| US-20040259918-A1 | Combination therapeutic compositions and method of use | TULARIK INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040219606-A1 | Methods, products and treatments for diabetes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-04 | — | — | US | disclosed |
| EP-1466628-A1 | DHA-pharmaceutical agent conjugates | Luitpold Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | PROTARGA, INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040166531-A1 | METHODS, PRODUCTS AND TREATMENTS FOR DIABETES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
| CN-1523980-A | Pharmaceutical formulations containing an active dispersed in a matrix | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | PROTARGA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| EP-1386165-A2 | INFLAMMATORY MARKERS FOR DETECTION AND PREVENTION OF DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6653332-B2 | For treatment of diabetes mellitus; for example sulfonamide derivatives of given formula and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, alpha-glucosidase inhibitors, glucagon antagonists | TULARIK INC. | 2003-11-25 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6602902-B2 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | PROTARGA, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030100486-A1 | Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | disclosed |
| US-20030059471-A1 | Oral delivery formulation | COMPTON BRUCE JON (US) | 2003-03-27 | — | — | US | disclosed |
| WO-2002048715-A2 | INFLAMMATORY MARKERS FOR DETECTION AND PREVENTION OF DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-20020037928-A1 | Combination therapeutic compositions and method of use | AMGEN INC. | 2002-03-28 | — | — | US | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001082916-A2 | COMBINATION THERAPEUTIC COMPOSITIONS AND METHODS OF USE | TULARIK INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000040604-A2 | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094693-A1 | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions | APOB, HBB, GCG | RAB9A 4331/4885PPARG 146/4885RXFP1 810/4885 |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | RAB9A 1335/4885PPARG 226/4885RXFP1 1420/4885 |
| US-20190241540-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | PGRMC2, PGRMC1, CYP3A43 | RAB9A 4314/4885PPARG 1615/4885RXFP1 1788/4885 |
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | RAB9A 290/4885PPARG 4517/4885RXFP1 3899/4885 |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | BMP2, CHERP, PUF60 | RAB9A 4232/4885PPARG 4110/4885RXFP1 1136/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | RAB9A 1335/4885PPARG 226/4885RXFP1 1420/4885 |
| US-20150284362-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | RAB9A 290/4885PPARG 4517/4885RXFP1 3899/4885 |
| US-20180334446-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-20080249156-A1 | Combinations of statins and anti-obesity agent and glitazones | HMGCR, DPP4, PPARG | RAB9A 2976/4885PPARG 3/4885RXFP1 1035/4885 |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | RAB9A 2019/4885PPARG 115/4885RXFP1 1807/4885 |
| US-20020037928-A1 | Combination therapeutic compositions and method of use | GPR119, GCGR, GLP1R | RAB9A 3819/4885PPARG 10/4885RXFP1 422/4885 |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | CRY1, CRY2, CRYAB | RAB9A 2071/4885PPARG 185/4885RXFP1 504/4885 |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | ADRA2C, ADRB3, ADRA2B | RAB9A 2949/4885PPARG 1413/4885RXFP1 1452/4885 |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | SI, TAS2R39, TAS2R31 | RAB9A 2156/4885PPARG 2440/4885RXFP1 1682/4885 |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | RAB9A 2921/4885PPARG 801/4885RXFP1 1649/4885 |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | IAPP, OGA, IDE | RAB9A 2163/4885PPARG 3921/4885RXFP1 4139/4885 |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | RAB9A 2073/4885PPARG 171/4885RXFP1 465/4885 |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | CRY1, CRY2, CRYAB | RAB9A 2073/4885PPARG 171/4885RXFP1 465/4885 |
| US-20180265589-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | RAB9A 290/4885PPARG 4517/4885RXFP1 3899/4885 |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | OPRL1, OPRM1, HTR2A | RAB9A 1005/4885PPARG 3843/4885RXFP1 2183/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | RAB9A 2015/4885PPARG 69/4885RXFP1 1249/4885 |
| US-20060063719-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | RAB9A 3497/4885PPARG 273/4885RXFP1 1244/4885 |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | ALOX12, FABP2, ALOX15B | RAB9A 3021/4885PPARG 433/4885RXFP1 3012/4885 |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | RAB9A 290/4885PPARG 4517/4885RXFP1 3899/4885 |
| US-20150315286-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | RAB9A 290/4885PPARG 4517/4885RXFP1 3899/4885 |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | CDH1, GPR119, FABP4 | RAB9A 457/4885PPARG 169/4885RXFP1 353/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | RAB9A 2600/4885PPARG 86/4885RXFP1 1721/4885 |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | SMURF1, SMURF2, SMS | RAB9A 3825/4885PPARG 319/4885RXFP1 3749/4885 |
| US-20040259918-A1 | Combination therapeutic compositions and method of use | GPR119, GCGR, GLP1R | RAB9A 3819/4885PPARG 10/4885RXFP1 422/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | RAB9A 271/4885PPARG 2056/4885RXFP1 1743/4885 |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-20070072830-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | RAB9A 3497/4885PPARG 273/4885RXFP1 1244/4885 |
| US-20110028460-A1 | TOPICAL FORMULATION | SPTLC1, SPTSSB, SPTLC3 | RAB9A 3625/4885PPARG 1200/4885RXFP1 4008/4885 |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | RAB9A 2015/4885PPARG 69/4885RXFP1 1249/4885 |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | RAB9A 1723/4885PPARG 477/4885RXFP1 2731/4885 |
| US-20100290987-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING O-GLYCOSYLATION | OGA, IAPP, IDE | RAB9A 2300/4885PPARG 3844/4885RXFP1 3778/4885 |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | SMURF1, SGMS1, SMURF2 | RAB9A 4463/4885PPARG 304/4885RXFP1 3967/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | RAB9A 3598/4885PPARG 330/4885RXFP1 4641/4885 |
| US-20060035928-A1 | Combination therapeutic compositions and methods of use | GPR119, GCGR, GLP1R | RAB9A 3906/4885PPARG 10/4885RXFP1 396/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | RAB9A 1649/4885PPARG 50/4885RXFP1 271/4885 |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | OPRM1, OPRL1, OPRK1 | RAB9A 813/4885PPARG 2483/4885RXFP1 3216/4885 |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | RAB9A 2373/4885PPARG 78/4885RXFP1 2127/4885 |
| US-20130079404-A1 | TOPICAL FORMULATION | SPTLC1, SPTLC3, SARAF | RAB9A 3460/4885PPARG 2024/4885RXFP1 4105/4885 |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | RAB9A 2073/4885PPARG 171/4885RXFP1 465/4885 |
| US-20130224211-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | RAB9A 290/4885PPARG 4517/4885RXFP1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.